|Application ||WB, IHC-P, E|
|Reactivity||Human, Mouse, Rat, Rabbit, Zebrafish, Monkey, Pig, Chicken, Horse, Xenopus, Bovine, Dog|
|Dilution||ELISA (1:32000), IHC-P (5 µg/ml), WB (0.2-1 µg/ml)|
|Other Names||E3 ubiquitin-protein ligase ARIH1, 6.3.2.-, H7-AP2, HHARI, Monocyte protein 6, MOP-6, Protein ariadne-1 homolog, ARI-1, UbcH7-binding protein, UbcM4-interacting protein, Ubiquitin-conjugating enzyme E2-binding protein 1, ARIH1, ARI, MOP6, UBCH7BP|
|Reconstitution & Storage||Store at -20°C. Minimize freezing and thawing.|
|Precautions||ARIH1 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin- conjugating enzyme E2 UBE2L3 (PubMed:15236971, PubMed:21532592, PubMed:24076655, PubMed:27565346, PubMed:23707686). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-RING ubiquitin ligase (CRL) complexes and initiating ubiquitination of CRL substrates: associates with CRL complexes and specifically mediates addition of the first ubiquitin on CRLs targets (PubMed:27565346). The initial ubiquitin is then elongated by CDC34/UBE2R1 and UBE2R2 (PubMed:27565346). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated cullin- RING ubiquitin ligase complexes (PubMed:24076655, PubMed:27565346). Plays a role in protein translation in response to DNA damage by mediating ubiquitination of EIF4E2, the consequences of EIF4E2 ubiquitination are however unclear (PubMed:25624349). According to a report, EIF4E2 ubiquitination leads to promote EIF4E2 cap-binding and protein translation arrest (PubMed:25624349). According to another report EIF4E2 ubiquitination leads to its subsequent degradation (PubMed:14623119). Acts as the ligase involved in ISGylation of EIF4E2 (PubMed:17289916).|
|Cellular Location||Cytoplasm. Nucleus. Nucleus, Cajal body. Note=Mainly cytoplasmic (PubMed:11278816). Present in Lewy body (PubMed:21590270)|
|Tissue Location||Widely expressed.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
E3 ubiquitin-protein ligase, which catalyzes polyubiquitination of target proteins together with ubiquitin- conjugating enzyme E2 UBE2L3. May play a role in protein translation by mediating polyubiquitination of EIF4E2, leading to its subsequent degradation. Acts as the ligase involved in ISGylation of EIF4E2.
Moynihan T.P.,et al.J. Biol. Chem. 274:30963-30968(1999).
Ardley H.C.,et al.Submitted (MAY-2002) to UniProtKB.
Trockenbacher A.,et al.Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Zody M.C.,et al.Nature 440:671-675(2006).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.